KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Equity Ratio: 2019-2025

Historic Equity Ratio for Royalty Pharma (RPRX) over the last 6 years, with Sep 2025 value amounting to 0.50.

  • Royalty Pharma's Equity Ratio fell 12.54% to 0.50 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.50, marking a year-over-year decrease of 12.54%. This contributed to the annual value of 0.57 for FY2024, which is 7.80% down from last year.
  • As of Q3 2025, Royalty Pharma's Equity Ratio stood at 0.50, which was down 4.12% from 0.52 recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Equity Ratio registered a high of 0.63 during Q2 2021, and its lowest value of 0.50 during Q3 2025.
  • For the 3-year period, Royalty Pharma's Equity Ratio averaged around 0.57, with its median value being 0.57 (2024).
  • As far as peak fluctuations go, Royalty Pharma's Equity Ratio climbed by 8.66% in 2023, and later decreased by 12.54% in 2025.
  • Royalty Pharma's Equity Ratio (Quarterly) stood at 0.59 in 2021, then dropped by 3.17% to 0.57 in 2022, then climbed by 8.66% to 0.62 in 2023, then decreased by 7.80% to 0.57 in 2024, then decreased by 12.54% to 0.50 in 2025.
  • Its Equity Ratio stands at 0.50 for Q3 2025, versus 0.52 for Q2 2025 and 0.56 for Q1 2025.